Legend Biotech (LEGN) Fundamental Analysis: Revenue, Earnings & Valuation

2.04 / 10

Underperform

Fundamental rating is Underperform with a 2.0/10 score. Revenue grew 64% YoY, yet cost of sales is high (39.7%). PB‑ROE and Revenue‑MV are negative, indicating valuation pressure and defensive outlook.

Analysis Checks(8/10)

Revenue-MV

Value-0.41

Score1/3

Weight22.00%

1M Return4.09%

Total operating revenue (YoY growth rate %)

Value64.02

Score2/3

Weight0.61%

1M Return0.13%

Inventory turnover ratio

Value14.60

Score2/3

Weight-5.05%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value86.99

Score2/3

Weight1.71%

1M Return0.36%

PB-ROE

Value1.25

Score0/3

Weight14.93%

1M Return2.74%

Long-term debt to working capital ratio (%)

Value0.16

Score3/3

Weight3.88%

1M Return0.87%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-5.14%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value64.02

Score2/3

Weight0.25%

1M Return0.05%

Cost of sales ratio (%)

Value39.66

Score3/3

Weight1.28%

1M Return0.26%

Asset-MV

Value-0.55

Score2/3

Weight65.53%

1M Return11.12%

Is LEGN undervalued or overvalued?

LEGN scores 2.04/10 on fundamentals and holds a Premium valuation at present. Backed by its -29.06% ROE, -28.85% net margin, -11.27 P/E ratio, 3.34 P/B ratio, and -68.75% earnings growth, these metrics solidify its Underperform investment rating.